TransMedics Group’s (TMDX) “Overweight” Rating Reaffirmed at Piper Sandler

Piper Sandler restated their overweight rating on shares of TransMedics Group (NASDAQ:TMDX) in a research report report published on Tuesday, Benzinga reports. Piper Sandler currently has a $180.00 price objective on the stock.

Other research analysts have also issued research reports about the stock. Canaccord Genuity Group dropped their price target on shares of TransMedics Group from $169.00 to $109.00 and set a “buy” rating for the company in a research report on Tuesday. Oppenheimer decreased their price target on TransMedics Group from $200.00 to $125.00 and set an “outperform” rating on the stock in a research note on Tuesday. JPMorgan Chase & Co. dropped their price objective on TransMedics Group from $173.00 to $116.00 and set an “overweight” rating for the company in a research note on Tuesday. Baird R W upgraded shares of TransMedics Group to a “strong-buy” rating in a research note on Tuesday, September 24th. Finally, Morgan Stanley increased their target price on shares of TransMedics Group from $104.00 to $145.00 and gave the stock an “equal weight” rating in a research report on Monday, July 15th. One analyst has rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $144.80.

TransMedics Group Trading Up 0.1 %

TransMedics Group stock opened at $81.97 on Tuesday. The business has a 50 day moving average price of $142.38 and a two-hundred day moving average price of $139.36. The company has a quick ratio of 8.48, a current ratio of 8.20 and a debt-to-equity ratio of 2.42. TransMedics Group has a 12 month low of $36.42 and a 12 month high of $177.37. The stock has a market cap of $2.75 billion, a price-to-earnings ratio of 87.20 and a beta of 1.99.

TransMedics Group (NASDAQ:TMDX) last issued its earnings results on Monday, October 28th. The company reported $0.12 EPS for the quarter, missing the consensus estimate of $0.29 by ($0.17). The firm had revenue of $108.76 million during the quarter, compared to the consensus estimate of $115.00 million. TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The firm’s revenue for the quarter was up 63.7% compared to the same quarter last year. During the same period last year, the business earned ($0.12) earnings per share. As a group, equities analysts forecast that TransMedics Group will post 1.11 EPS for the current year.

Insider Buying and Selling at TransMedics Group

In other news, CEO Waleed H. Hassanein sold 8,625 shares of the company’s stock in a transaction on Monday, September 16th. The stock was sold at an average price of $153.42, for a total transaction of $1,323,247.50. Following the transaction, the chief executive officer now owns 61,643 shares of the company’s stock, valued at $9,457,269.06. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. In related news, insider Nicholas Corcoran sold 10,000 shares of TransMedics Group stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $176.02, for a total transaction of $1,760,200.00. Following the completion of the sale, the insider now directly owns 21,105 shares of the company’s stock, valued at $3,714,902.10. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Waleed H. Hassanein sold 8,625 shares of the business’s stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $153.42, for a total value of $1,323,247.50. Following the transaction, the chief executive officer now owns 61,643 shares of the company’s stock, valued at $9,457,269.06. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 61,247 shares of company stock worth $9,518,181. Insiders own 7.00% of the company’s stock.

Institutional Investors Weigh In On TransMedics Group

Several hedge funds have recently bought and sold shares of the company. Vaughan Nelson Investment Management L.P. acquired a new stake in shares of TransMedics Group during the second quarter worth about $39,862,000. Driehaus Capital Management LLC lifted its holdings in shares of TransMedics Group by 15.8% in the second quarter. Driehaus Capital Management LLC now owns 1,486,073 shares of the company’s stock valued at $223,832,000 after purchasing an additional 202,867 shares in the last quarter. Principal Financial Group Inc. boosted its position in shares of TransMedics Group by 260.1% during the third quarter. Principal Financial Group Inc. now owns 202,287 shares of the company’s stock worth $31,759,000 after buying an additional 146,115 shares during the period. Hood River Capital Management LLC bought a new position in shares of TransMedics Group during the second quarter worth about $18,854,000. Finally, Canada Pension Plan Investment Board acquired a new stake in TransMedics Group in the 2nd quarter valued at approximately $16,086,000. 99.67% of the stock is currently owned by institutional investors and hedge funds.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.